Tuesday, January 26, 2021

#Biotech #Podcast - Sigyn Therapeutics (OTC:$SIGY) Talks about Treatment of #Cytokine Storm Syndrome- leading cause of death related to severe #COVID19 infections and sepsis; @Sigyn_inc

#Biotech #Podcast - Sigyn Therapeutics (OTC:$SIGY) Talks about Treatment of #Cytokine Storm Syndrome- leading cause of death related to severe #COVID19 infections and sepsis; @Sigyn_inc 

 

Point Roberts WA, Delta BC, January 26, 2021 - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today’s special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) Chairman and CEO, Jim Joyce.

 

Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc. (NASDAQ: AEMD)

 

Listen to today’s Podcast:  

https://www.investorideas.com/Audio/Podcasts/2021/012021SIGY-CEO-Interview.mp3

 

Read this in full at https://www.investorideas.com/news/2021/biotech/01261SIGY-Cytokine-Storm-Syndrome.asp

 

Listen to Investor Ideas podcasts on Spotify

 

Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, “Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections.  It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion.”  Mr Joyce added that: “Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies.”

 

Mr. Joyce further discussed how the limitations of single-target drugs have created an increased interest in extracorporeal blood purification technologies that can address a broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are limited to a single Cytokine target.

 

Continued: “We really see two pioneering devices and they happen to be associated with public companies. One is the CytoSorb device from CytoSorbents Corporation (NASDAQ: CTSO) which has a market value of approximately $400 million. This device is designed to reduce the presence of a broad-spectrum of inflammatory cytokines from circulation.”

 

Continued: “The other device is the Toraymyxin Device which is a product of Toray Industries, Inc. (3402.T) based in Japan.  This is one of about several products from Toray that drives a market value of about $10 billion. The Toraymyxin product eliminates circulating endotoxins, which is a potent activator of the cytokine storm.”

 

Continued: “However, it does not address inflammatory Cytokines.  Inversely, CytoSorb addresses inflammatory Cytokines but doesn't address endotoxin. So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory Cytokine cargos throughout the circulatory system (OTCMarkets: SIGY).”

 

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California, USA. Their focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

Joyce also discusses his previous leadership role at Aethlon Medical, Inc. (NASDAQ: AEMD) where he oversaw the development of the Hemopurifier to treat life-threatening viral infections and address tumor-derived exosomes in cancer patients as a great experience prior to founding Sigyn Therapeutics, Inc.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

 

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) is Working on its #qTerm Device Improvements as a Preparation for its #FDA Certification Process

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) is Working on its #qTerm Device Improvements as a Preparation for its #FDA Certification Process

 


San Diego, CA, January 26, 2021 – (Investorideas.com Newswire) - GBT Technologies Inc. (OTCPINK: GTCH) ("GBT”, or the “Company”) via GBT Tokenize Corp (“GBT/Tokenize”) , has started a series of improvements for its qTerm device as preparations for FDA certification process. The series of improvements are targeting higher measurements accuracy, reliability and compatibility with a broad spectrum of user’s usage behavior. qTerm is aimed to measure human vitals with a touch of a finger. Based on prototype testing, debugging and study, conclusions were made in order to increase the device’s accuracy and stability as expected pre-requisites towards the company’s intentions to file for FDA certification. There is no guarantee that the company or GBT/Tokenize will receive FDA certification for the qTerm. 

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01261qTerm-Preparation-FDA.asp

 

qTerm first release will include body temperature, blood oxygen and heart rate vitals. The next release is planned to include blood pressure measurement. In order to increase consistency with user’s measurement habits, the device’s sensors will be re-located to more efficient positions to enable best and consistent results. For example, different users may press their finger using different pressure, and position. The body heat sensor’s accuracy is highly dependent on its distance from the finger’s skin. A new location of the IR (Infra-Red) sensor will be defined to enable an optimum distance to accommodate different user’s pressing pressure and position. The heart rate and SPO2 (Blood Oxygen) sensor needs a direct skin contact again with proper adjustments to different user’s finger’s pressure, position and stability. An additional microchip will be installed to provide an expert algorithm to support broad user’s measuring habits, compensating for different inputs, and providing a consistent results for heart rate and blood oxygen data. The device will be accompanied by a smartphone app and synchronized web application to keep a history and provide analytics for user's records. It is the goal for the web application to provide a geographical location and proximity alert to assist with potential health risks. The series of modifications are done as preparations for an FDA certification to classify qTerm as a medical device to be marketed and sold in the US. The certification process is also aimed to define the device for telemedicine purposes enabling remote vitals results to be sent to clinics and hospitals for physicians review in real time.

 

"We believe these changes will significantly increase the device’s performance, accuracy, and consistency we are required to meet during the FDA certification. We believe these changes will ensure the product's safety, accuracy, and reliability along with high quality and efficiency. This technology, assuming we receive FDA certification of which there is no guarantee, is planned to be marketed and sold for personal and clinics usage also targeting it for the telemedicine arena. Another aspect is the device’s planned Artificial Intelligence technology that will be offering advanced features like real-time health statistics, analytics, monitoring and real time, geographically proximity alert to assist with avoiding health risks. The modifications also are focus on human engineering aspect in order to ensure easier usability for the vitals measurements like finger’s position pointers and physical finger’s location structural design. We put extra emphasis on making the device easy for use, mainly intuitive. Vitals results can be crucial indicators to assist with early detection of illness and we are working to improve the device’s performance and capabilities as preparations efforts for FDA clearance. It is in our R&D culture to constantly improve our technology in efforts to bring it to the highest standards and regulations, particularly in the medicine domain when it can save lives." Said Danny Rittman GBT/Tokenize and the Company’s CTO.

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 


  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

 

 

 

 

 

Monday, January 25, 2021

#AIEye #Podcast 512: Royal Philips (NYSE: $PHG) Signs Research and Innovation Partnership with Rennes University, EHAVE (OTC: $EHVVF) Plans to Address Big Data Management in Mental Healthcare with #AI/ #ML


 

 

#AIEye #Podcast 512: Royal Philips (NYSE: $PHG) Signs Research and Innovation Partnership with Rennes University, EHAVE (OTC: $EHVVF) Plans to Address Big Data Management in Mental Healthcare with #AI/ #ML

 

Global #Blockchain AI Market to Reach $973.6 Million by 2027

 

Point Roberts WA, Vancouver BC – January 25, 2021  – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of  The AI Eye-  watching stock news, deal tracker and advancements in artificial intelligence

 

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2021/012521-AI-Eye.mp3

 

Read this in full at https://www.investorideas.com/news/2021/artificial-intelligence/01251PHG-Rennes-University.asp

 

Hear the Ai Eye on Spotify  

 

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

 

Stocks discussed: (NYSE:PHG) (OTC:EHVVF)

 

Royal Philips (NYSE:PHG) has announced the signing of a 5-year technology and innovation partnership with Rennes University Hospital “to support diagnostic, interventional imaging and patient monitoring and management, undertake clinical research, and leverage Philips’ and Rennes University Hospital’s ecosystems of open innovation to foster French start-up companies.” David Corcos, General Manager Philips France, explained:

 

“Philips and Rennes University Hospital are entering into a ground-breaking partnership aimed at significantly improving the stroke pathway and co-developing AI algorithms to improve care for the most acute patients, particularly those in the ICU. Leveraging the hospital’s clinical expertise and our respective innovation ecosystems, we believe we can jointly innovate to help the hospital’s healthcare professionals improve care and outcomes for their patients, while contributing to a more sustainable healthcare system. We are thrilled by this unique opportunity.”

 

Digital therapeutics firm EHAVE, Inc. (OTC:EHVVF) has announced plans to continue to address the needs of big data management in mental healthcare using AI and machine learning. Ben Kaplan, CEO of Ehave, explained:

 

“Ehave moved predictive analytics to the forefront for mental health. The acceleration and acceptance of digital technology in 2021 means more health systems now have the technical capabilities to practice precision medicine as they move closer to predictive analytics. The Ehave dashboard has machine learning-powered models to identify high risk and the likelihood of problems among mental health patients. This offers healthcare providers more efficient patient management.”

 

 

Global Blockchain AI Market to Reach $973.6 Million by 2027

 

A report published by Fortune Business Insights finds that the global Blockchain AI market will grow from $220.5 million in 2020 to $973.6 million in 2027 with a compound annual growth rate (CAGR) of 23.6 percent in that forecast period. An excerpt from the report summary highlights the role of NLP in the market:

 

“The increasing demand for the combination of blockchain and AI-based natural language processing (NLP) solutions among large enterprises is expected to be one of the key trends for the growth of this market. The intervention-free and fault-tolerant features combined with the non-modifiable, irreversible, and immutable characteristics of blockchain are vital for the security of the sensitive data generated by NLP solutions and algorithms. Blockchain solutions based on NLP help end-users to expand applications such as ERP [enterprise resource planning] systems, security management systems, and others.”

 

Sam Mowers, Investorideas.com

 

Read and hear other editions of the AI  Eye

 

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

The AI Eye-  Watching stock news, deal tracker and  advancements in artificial intelligence is an original content brand of Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 




Get more Technology stock investor ideas - news, articles, podcasts and stock directories

 

Investor Ideas #Potcasts 522, #Cannabis News and #Stocks on the Move (TSX: $VLNS.TO) (CSE: $HOLL.C) (CSE: $HARV.C) (CSE: $CURA.C)

 



 

Investor Ideas #Potcasts 522, #Cannabis News and #Stocks on the Move (TSX: $VLNS.TO) (CSE: $HOLL.C) (CSE: $HARV.C) (CSE: $CURA.C)

 

Delta, Kelowna, BC, January 25, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/012521-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/01251VLNS-HOLL-HARV-CURA.asp

 

Hear the investor ideas potcast on Spotify

 

Hear Investor ideas cannabis potcast on iTunes  

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be looking at a few public company announcements.

 

The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCFannounced that it has entered into a definitive agreement to acquire all of the issued and outstanding shares of LYF Food Technologies Inc. in a cash and share transaction for closing consideration of CDN$24.9 million, plus up to an additional CDN$17.5 million in consideration payable upon the business achieving certain earn-out EBITDA milestones. The LYF Acquisition is expected to be accretive to the Company's EBITDA and diluted EPS in 2021, and if all of the Milestones are met, the transaction represents an approximate ~4.2x multiple on the last milestone achieved. With the LYF Acquisition, The Valens Company not only strengthens its already wide-reaching production capabilities for the 2.0 and 3.0 markets, but also unlocks significant growth potential with the addition of a cutting-edge platform designed to capitalize on one of the fastest growing product segments in the cannabis industry.

 

LYF is a premier edibles manufacturer based in Kelowna, British Columbia with expertise in novel product creation, white label manufacturing and infusion technologies. Similar to Valens, LYF operates a product development and manufacturing platform focused on consumer-driven innovation, and product safety and consistency. LYF brings a proven team with significant experience producing high throughput food products, in addition to experience operating and working with major Canadian grocery chains, health and wellness retailers, and pharmacies. Just minutes away from Valens' headquarters, LYF's purpose-built manufacturing facility produces innovative edible products using the highest quality ingredients and cannabis extracts, offered in proprietary delivery methods.

 

Valens' access to low-cost active ingredients paired with LYF's industry-recognized product IP formulations of over 100 recipes strengthens its capabilities to produce higher-margin, new-to-market edible formats in a segment with limited product variability, and increased consumer demand. With the added infrastructure and expertise from the LYF Acquisition, The Valens Company significantly expands its edibles footprint and strategy to remain a best-in-class manufacturing platform for its partners, while also increasing its ability to capture market share in the rapidly growing product category. Similar to consumer trends in the US cannabis market, edible products are anticipated to represent over 10% of sales in the maturing Canadian cannabis market.

 

Tyler Robson, Chief Executive Officer and Chair of the Board of The Valens Company, said, "LYF has set the standard of what high quality edibles should be and has developed a diverse and flexible manufacturing platform to play a dominant role in the Canadian edibles market. LYF stood out for its product innovation and marketing teams, as well as its broad range of edible products which will introduce new formats to Canadian consumers that are typically only available in more mature markets. We look forward to further developing our product offering to reach more consumers with high-quality and unique cannabis edibles as this product segment continues to gain in popularity."

 

"Our team could not be more thrilled to join forces with The Valens Company and collectively fuel our shared passion for producing exceptional cannabis products with consumers top of mind," said Paolo Pero and Matthew Amado, Founders of LYF. "As a fellow Kelowna-based company, Valens' vision for global growth resonated with the team and ultimately led us to recognize the significant value in combining what we have each uniquely created to bring a new level of manufacturing excellence to Canada and beyond."

 

 

 

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF), diversified cannabis branding company with products in over 98 dispensaries throughout Arizona, commended the state of Arizona for its efficient activation of adult-use cannabis sales. Legal sales of adult use cannabis in Arizona commenced mid-day on Friday January 22nd, 2021, several months ahead of industry expectations, and the fastest that any of the 15 states with recreational marijuana has gone from voter approval to actual sales.

 

The company's wholly owned subsidiary, Venom Extracts product suite is a category leader with over 4 million grams sold in 2020, accounting for up to 30 percent of category sales state-wide. Venom is positioned for continued growth in Arizona, it has a strong brand recognition and distribution network, its products are available at leading retailers including Harvest Health and Recreation (CSE: HARV) (OTCQX: HRVSF), Curaleaf (CSE: CURA) (OTCQX: CURLF), Bloom, MuV and Oasis Cannabis dispensaries among others.

Arizona voted to legalize adult use cannabis in November, "Marijuana Business Daily projects that the state's recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024".

 

"Medical-marijuana dispensaries that got approved to sell recreational marijuana on Friday include 13 of the 15 Harvest shops in the state, all eight Curaleaf shops, The Mint locations in Guadalupe and Mesa, three Territory Dispensary locations, and dozens of others in places across the state, including in Tucson, Yuma, Flagstaff, Cottonwood and Sedona. Arizona Department of Health Services spokesman Steve Elliott said Friday that the department had approved 86 applications. Some dispensaries in the state are still waiting to file their applications because they are not yet prepared to offer recreational sales, which are expected to bring substantially more traffic to their stores". As reported by AZ Central on January 22nd, 2021.

 

In 2020, sales of medical cannabis in Arizona grew by greater than 27%, as such Venom has been a catalyst for revenue growth of the Company. On March 26th, 2020 (see press release dated March 30th, 2020), Hollister Biosciences acquired Venom Extracts and since the closing, in the three quarters following, Venom contributed approximately CDN$38 million to the company's 2020 revenue.  In the entire year of 2020, Venom Extracts generated greater than CDN$ 40 million in revenue (and CDN$4.8 million in adjusted EBITDA), up from CDN$16.4 million in 2019 a 144% year over year increase, and ending the year with a record month of sales for December totaling approximately CDN$5.5 million. These unaudited numbers represent record sales for the company, and the expectation is that sales growth will continue in 2021.

 

In addition to continued revenue growth, the company plans to focus on core growth area's including; enhancing; unit margins, market penetration, loyalty and same-store sales.

Some additional highlights of the company include:

       Branded Products now on sale in over 370 cannabis dispensaries in Arizona and California

       4 owned brands, and 3 brand collaborations

       Over 4 million grams sold

       Over 96,000 lbs. of cannabis biomass converted into finished products in Arizona

       Total sales for 2020 increased 3233% from 2019 and are estimated to be approximately CDN $40 million

       December 2020 sales totaled greater than CDN$6 million

The Company looks forward to continuing execution of its business plan and growth targets in 2021, primarily focused on the exponential growth anticipated in and continued market penetration of branded products throughout California.

 

 Global Trac Solutions, Inc. (OTC: PSYC), a digital media leader within the emerging sector of medicinal psychedelics, announced that the Company has entered into a Joint Venture Partnership with Minerco, Inc. (OTC: MINE), a Jamaican-based company specializing in growing, research, production and distribution of psilocybin mushrooms and marketing worldwide.

 

The JV creates an opportunity for the companies to collaborate on the co-development and hosting of virtual conferences and forums focused on educating, informing, and showcasing the potential medicinal benefits of psilocybin mushrooms, including the psilocybin-based products MINE is developing. Additionally, the JV allows for PSYC to serve as one of the primary digital marketing partners for MINE as they move forward with their focus of bringing their products to market.

 

“We are extremely delighted to partner with MINE, a company that is deeply-rooted in the sector of psilocybin mushrooms,” said Global Trac Solutions, Inc. CEO, David Flores. “And we’re thrilled to be able to combine our collective resources to develop and produce virtual conferences and forums in the coming months that we believe will effectively highlight this exciting sector within the psychedelic industry.”

 

“To JV with PSYC will be a great opportunity for both companies,” said Julius Jenge, Minerco, Inc. CEO. “MINE will have the ability to do real case studies using our own product and PSYC will be able to track the research with their media platform. This initiative will allow us to host forums with both industry experts and patients who will give real examples of the benefits of Psilocybin and more specifically MINE products.”

 

The companies intend to be able to collectively develop and produce their first joint virtual conference/forum within the next two months and will release more information to the public related to specific dates and times as soon as it is available.

 

“As our industry continues to gain more exposure and develop more momentum behind it, I believe we will continue to see an increase, globally, for platforms, such as Psychedelic Spotlight, that provide access to a wealth of informational and educational resources focused on this paradigm shift in healing and treatment that psychedelics like psilocybin are creating,” Flores said. “As MINE continues its focus on developing quality psilocybin-based products, we here at PSYC look forward to leveraging our expanding media platform and network to contribute to their growth and success in the months to come.”

 

 

CannabizTeam, the world's largest cannabis-focused executive search and staffing firm, has launched a new service line for cannabis companies: CT Board Placement. CT Board Placement assists cannabis industry clients in identifying and recruiting candidates for Board of Director positions who have a diverse blend of skills and experience that match the strategic direction of each client.

 

"Appointing the right non-executive directors is a critically important decision for all cannabis companies in today's competitive marketplace," said Liesl Bernard, CEO of CannabizTeam. "Recruiting directors in the cannabis space is a more complex process due to the relative youth of the industry and the lingering legacy legal nuances. Our goal with CT Board Placement is to help our clients find a diverse blend of candidates with relevant experience, strong character and reputation, proven judgment and leadership skills that will set them up for future success."

 

Board of Director diversity reflects one of the core values of CT Board Placement, which is especially relevant as the cannabis industry has continued to lead corporate America in social equity and corporate social responsibility programs. CannabizTeam is committed to promoting fairness, justice and equity in the cannabis industry, and will work to fill Board of Director positions with individuals of all genders, religions and races.

 

CT Board Placement will also offer a Cannabis Director Development Program to help first-time directors learn the culture and nuances of the company they will serve as well as the broader cannabis industry. The Cannabis Director Development Program includes a detailed curriculum exploring the most relevant governance issues in North America, with a special focus on issues facing boards in the U.S., Canadian and Mexican cannabis markets.

 

CT Board Placement is a division of CannabizTeam Worldwide, which also operates CT Executive Search, CannabizTeam Direct Hire and CannabizTemp. Through its four staffing divisions, CannabizTeam fills more than 1,000 cannabis positions each year in all verticals of the industry across the globe. CannabizTeam's proprietary database includes more than 100,000 successful executives with experience in and beyond the cannabis industry – an excellent resource for cannabis companies searching to fill Board of Director positions.

 

To learn more about CT Board Placement, visit: https://cannabizteam.com/cannabis-board-of-directors-recruitment/.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory